A股異動 | 上半年業績符預期 我武生物(300357.SZ)放量漲7%
格隆匯7月16日丨我武生物(300357.SZ)午後漲至7%,報70.6元,成交額放大至5.2億元,總市值370億元。我武生物15日晚公佈,2021年半年度營業收入為3.48億元,同比增長33.99%;歸母淨利潤1.47億元,同比增長37.61%。國盛證券指出,公司業務迴歸正軌,業績符合預期,粉塵蟎滴劑逐季恢復增長。預計Q3起,隨着局部疫情偶發因素吿一段落,公司收入端有望恢復至30%的正常增速。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.